Get the Stockscreener App
1.12
5.08%
-0.06
Io Biotech Inc stock is traded at $1.12, with a volume of 75,897.
It is down -5.08% in the last 24 hours and down -2.61% over the past month.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$1.18
Open:
$1.16
24h Volume:
75,897
Relative Volume:
0.19
Market Cap:
$77.74M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.4358
EPS:
-2.57
Net Cash Flow:
$-72.06M
1W Performance:
-13.51%
1M Performance:
-2.61%
6M Performance:
-24.32%
1Y Performance:
+25.84%
1-Day Range:
$1.11
$1.19
1-Week Range:
$1.11
$1.36
52-Week Range:
$0.7327
$2.098
Io Biotech Inc Stock (IOBT) Company Profile
Name
Io Biotech Inc
Sector
Industry
Phone
(457) 070-2980
Address
OLE MAALOES VEH 3, COPENHAGEN
Io Biotech Inc Stock (IOBT) Latest News
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation - Yahoo Finance
Legend Biotech Chooses Philadelphia for New R&D Center - BioBuzz
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 12.7% - MarketBeat
Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
IO Biotech, Inc. (NASDAQ:IOBT) Shares Sold by Novo Holdings A S - MarketBeat
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, Companies by DelveInsight - Barchart
38,076 Shares in Montauk Renewables, Inc. (NASDAQ:MNTK) Bought by Squarepoint Ops LLC - Defense World
Bank of America Boosts Voya Financial (NYSE:VOYA) Price Target to $88.00 - Defense World
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Norstella introduces a fully integrated data asset for biopharma - European Pharmaceutical Manufacturer
Immuno-Oncology Clinical Trials Market Valuation to Reach $18.1 Billion By 2032 - 대구포스트
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - ForexTV.com
VerImmune Secures $4.5 Million to Drive Biotech Innovation - BioBuzz
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - The Manila Times
ARHT Media Inc. Announces Filing for Bankruptcy - The Manila Times
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting - Marketscreener.com
United States shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
5 Best Microbiome Companies (November 2024) - Securities.io
ProShare Advisors LLC Sells 113 Shares of Reinsurance Group of America, Incorporated (NYSE:RGA) - Defense World
Novo Holdings A S Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT) - MarketBeat
American Century Companies Inc. Purchases 75,475 Shares of Lifetime Brands, Inc. (NASDAQ:LCUT) - Defense World
PCI Pharma Services invests over $365 million in EU and US facilities - European Pharmaceutical Manufacturer
Sei Investments Co. Buys 24,363 Shares of IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Cancer Vaccines Market Detailed In Recent Development to Grow - openPR
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
Investors in cash trouble should check out IO Biotech Inc (IOBT) - SETE News
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
IO Biotech (NASDAQ:IOBT) Rating Reiterated by HC Wainwright - Defense World
IO Biotech (NASDAQ:IOBT) PT Raised to $6.00 - Defense World
IO Biotech Inc [IOBT] moved up 3.22: Why It’s Important - The DBT News
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Piper Sandler maintains Overweight rating on IO Biotech shares By Investing.com - Investing.com Canada
Analyzing IO Biotech Inc (IOBT) After Recent Trading Activity - Knox Daily
IOBT (IO Biotech Inc) has impressive results - US Post News
Market Momentum: IO Biotech Inc (IOBT) Registers a -2.20 Decrease, Closing at 0.75 - The Dwinnex
Non Small Cell Lung Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024 - Barchart
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Examining the Potential Price Growth of McDonald’s Corp (MCD) - Knox Daily
Piper Sandler maintains Overweight rating on IO Biotech shares - Investing.com
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - StockTitan
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer - Marketscreener.com
IOBT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
IO Biotech Inc’s results are impressive - US Post News
IO Biotech Inc [IOBT] Insider Activity: An Update for Investors - Knox Daily
Ratios in Focus: Analyzing IO Biotech Inc (IOBT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Morgan Stanley maintains Overweight rating on IO Biotech shares By Investing.com - Investing.com Canada
IO Biotech stock hits 52-week low at $0.8 amid market challenges - Investing.com Canada
It is Poised to be a Bull Market for IO Biotech Inc (IOBT) - SETE News
Io Biotech Inc Stock (IOBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):